Skip to Content

Jennifer J. Wheler, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

  • Targeted therapies
  • Novel mechanisms of action
  • Early combination trials 
  • Personalized medicine
  • Genomics
  • Breast cancer

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit 455
Houston, TX 77030
Room Number: FC8.3052
Phone: 713.745.9246
Fax: 713.794-4130

Education & Training

Degree-Granting Education

1999 Weill Medical College of Cornell University, New York, NY, MD, Medicine

Postgraduate Training

2004-2006 Special Fellow, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY
2002-2004 Fellowship, Oncology, Yale University Comprehensive Cancer Center, New Haven, CT
1999-2002 Residency, Internal Medicine, Columbia-Presbyterian Medical Center, New York, NY

Board Certifications

11/2008 American Board of Internal Medicine, Medical Oncology
8/2003 American Board of Internal Medicine,


Academic Appointments

Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2006-7/2014

Selected Publications

Peer-Reviewed Original Research Articles

1. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens P, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget 5(10):3029-38, 5/2014. PMID: 24912489.
2. Wheler JJ, Parker BA, Lee JJ, Atkins JJ, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero, V, Schwaederle M, Yelensky R. Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique Molecular Signatures as a Hallmark of Patients with Metastatic Breast Cancer: Implications for Current Treatment Paradigms. Oncotarget 5(9):2349-54, 5/2014.
3. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook G, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. e-Pub 3/2014.
4. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 73(3):495-501, 3/2014. PMID: 24435060.
5. Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLOS One 9(2):e89388, 2/2014.
6. Wheler JJ. Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther 12(10):2167-2175, 10/2013. PMID: 23963360.
7. Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget 4(6):890-898, 6/2013. PMID: 23765114.
8. Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul S, Chen S, Heymach J, Fu S, Stephen B, Fok J, Janku F, Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget 4(5):772-84, 5/2013. PMID: 23800712.
9. Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol 24(3):838-42, 3/2013. PMID: 23139256.
10. Janku F, Wheler JJ, Hong DS, Kurzrock R. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol, 2/2013. e-Pub 2/2013. PMID: 23400451.
11. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials. Cancer Res 73(1):276-84, 1/2013. PMCID: PMC3537862.
12. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 3(12):1566-75, 12/2012. PMID: 23248156.
13. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Risk of serious toxicity in 1,181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol 23(8):1963-7, doi: 10.1093/annonc/mds027, 8/2012. e-Pub 2/2012. PMCID: PMCPMC4092254.
14. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. Phase I study of RO4929097, a gamma secretase inhibitor of notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30(19):2348-53, 7/2012. PMID: 22529266.
15. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res 18(10):2922-9, 5/2012. PMID: 22452943.
16. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-82, 3/2012. PMCID: PMC3295566.
17. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: The M. D. Anderson Cancer Center experience. Gynecol Oncol 117(3):467-72, 6/2010. PMCID: PMC2882061.
18. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic. Clin Breast Cancer 10(1):46-51, 2/2010. PMID: 20133258.
19. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a phase I clinic: the M. D. Anderson Cancer Center experience. Cancer 115(5):1091-99, 3/2009. PMID: 19165805.
20. Wheler J, Johnson M, Seidman A. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. Semin Oncol 33(6):672-80, 12/2006. PMID: 17145347.

Last updated: 9/23/2014